Clinical Trial Search

Primary: Mean Summed Pain Intensity (SPI) Score Over 24 Hours — 69.16; 96.83; 83.38; 85.70 Units on a scale

Primary: Muscle Mass Change: From Dual Energy X-ray Absorptiometry and Bioelectrical Impedance Analsysis - Appendicular Lean Mass (ALM in kg) Divided by Height (Meters-squared)…

Primary: Visual Analog Scale (VAS) Pain Score in the Abdominal, Arm, Thigh, and Buttock Areas — 3.4; 2.0; 1.8; 1.9 millimeter

Primary: Median Fold Change of Cytokine Levels From Day 0 to Day 90 — 3254; 1.997; 16.83; -33.89 pg/mL

Primary: Cohort 1: Geometric Mean Antibody Titers to Respiratory Syncytial Virus (RSV) Prefusion Conformation-stabilized F (preF) Protein Using preF Enzyme-linked Immunosorbent…

Primary: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAEs) — 7; 1 Participants

Primary: Peak Changes on Items of the Drug Effects Questionnaire (DEQ) - Stimulatory Effects — 7.03; 37.48; 41.91; 28.22 score on a scale

Primary: Change From Baseline in Total Urinary Incontinence Episodes — -1.99; -1.7 episodes per day — p=0.056

Primary: Cumulative Non-Fatal VTE Recurrence at 6 Months (%) — 6.1; 8.8; 7.5; 4.1 percentage of patients

Primary: Prostate Specific Antigen (PSA) Response to Bipolar Androgen Therapy + Nivolumab — 18 Participants

Primary: Number of Subjects Whose Endoscopic Images Correlated With Final Clinical and Histological Diagnosis — 283 participants

Primary: Geometric Mean Concentrations (GMCs) of Pneumococcal Immunoglobulin G (IgG) by Cohort — 1.55; 0.12; 0.42; 0.07 microgram per milliliter (µg/mL)

Primary: Percent Reduction From Baseline in Cough Frequency (Cough Events Per Day) to the Average of Week 8 Through Week 12 — 91.7 percent reduction

Primary: Number of Participants With Worst Pain Score of Moderate to Severe on the Brief Pain Inventory — 1497; 1535 Participants

Primary: Maximum Tolerated Dose (MTD) — 400 Milligram (mg)